Asmanex
AsmanexAsmanex is a metered-dose powder for inhalation, which is recommended for the persistent type bronchial asthma treatment, when seizures occur more often than 1 time per week. The main active ingredient has anti-inflammatory and anti-allergic effects. The therapeutic effect is achieved with a minimum medication dose. Detailed information about the drug, the features of use, read the instructions.
Indications for use (instruction): Asmanex
Systematic treatment to control persistent bronchial asthma.
How to use
The drug is used for the systematic treatment of adults and children over 12 years old suffering from bronchial asthma of any severity, including hormone-dependent (patients who use systemic or inhaled corticosteroids).
The drug is used only for inhalation.
Recommended doses depend on the severity of bronchial asthma.
Mild to moderate asthma
The recommended initial dose of Asmanex® for most patients is 400 mcg once a day. Research has shown that inhalation should be performed in the evening to achieve better control. In some patients, a more effective control of the disease occurs when the daily dose of 400 μg is divided into 2 inhalations (200 μg twice a day).
The dose should be determined individually and gradually reduced to the minimum, which provides adequate control over the course of asthma. For some patients, the effective maintenance dose can be reduced to 200 mcg once daily in the evening.
Severe asthma
The initial recommended dose of Asmanex® is 400 mcg 2 times a day, which is the maximum recommended dose. After achieving effective control of asthma symptoms, the dose of Asmanex® should be gradually reduced to the minimum effective.
Patients with severe asthma who have previously received oral corticosteroids, start taking Asmanex® in parallel with the patient’s usual maintenance dose of systemic corticosteroids. After about one week, you can gradually stop the use of systemic GCS by reducing the daily dose at intervals of one to two weeks, depending on the patient's response to treatment. As a rule, such reductions should not exceed 2.5 mg of prednisone per day or its equivalent.
It is strongly recommended that you stop using systemic corticosteroids very slowly. During the abolition of oral corticosteroids, patients should be carefully monitored for manifestations of unstable asthma, in particular by objective measurement of respiratory function, as well as regarding manifestations of adrenal insufficiency.
The patient should be instructed that the drug Asmanex® is not indicated as a drug that is used if necessary to relieve acute symptoms, and this drug should be taken regularly to maintain therapeutic benefit, even if the patient does not have symptoms of the disease.
Children under 12 years old
There is no clinical experience with the use of the drug in this age group.
Elderly patients
There is no need for dose adjustment. The patient should be instructed on how to use the inhaler correctly.
Read more about the rules for using the Twistheiler inhaler in the instructions.
Contraindications
Hypersensitivity to the active substance or excipient (lactose, which contains residual milk proteins).
Composition
Active substance: mometasone;
1 dose contains 200 mcg or 400 mcg of mometasone furoate.
Excipients: lactose.
Release form
30 doses or 60 doses in a Twistheiler® packed in aluminum foil laminated with a plastic film in a cardboard box.
Storage conditions
Keep out of reach of children in the original packaging at a temperature not exceeding 30 °C. Do not refrigerate.
Manufacturer
Schering-Plough Labo NV, Industriepark 30, Heist-op-den-Berg, 2220, Belgium.
Registration certificate
№1625 dated 07/17/2019.